Vestmark Advisory Solutions’s BioMarin Pharmaceuticals BMRN Stock Holding History

Vestmark Advisory Solutions’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,352	Closed	-$384K	–	861
2021 Q4	$384K	Buy	4,352 +165	+4%	+$13.6K	0.02%	616
2021 Q3	$324K	Buy	4,187 +179	+4%	+$14.1K	0.02%	637
2021 Q2	$334K	Buy	4,008 +50	+1%	+$3.96K	0.02%	595
2021 Q1	$299K	Sell	3,958 -1,426	-26%	-$116K	0.03%	601
2020 Q4	$472K	Sell	5,384 -153	-3%	-$12.1K	0.05%	366
2020 Q3	$421K	Buy	5,537 +860	+18%	+$87K	0.06%	351
2020 Q2	$577K	Buy	4,677 +229	+5%	+$22.8K	0.09%	279
2020 Q1	$376K	Buy	+4,448	New	+$383K	0.07%	312
2019 Q4	–	Sell	-4,445	Closed	-$300K	–	288
2019 Q3	$300K	Buy	4,445 +1,060	+31%	+$81.6K	0.05%	410
2019 Q2	$290K	Buy	+3,385	New	+$290K	0.05%	415

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vestmark Advisory Solutions's BMRN Position: Q1 2022 in Review

Vestmark Advisory Solutions sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 4,352 shares — an estimated $384K sold.

Vestmark Advisory Solutions first reported a position in BMRN in Q2 2019 and held it in 10 quarters. The position peaked at $577K in Q2 2020. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Vestmark Advisory Solutions reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Vestmark Advisory Solutions sold 4,352 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $384K.
Vestmark Advisory Solutions first reported a position in BioMarin Pharmaceuticals in Q2 2019 and held it in 10 quarters.
Vestmark Advisory Solutions's BioMarin Pharmaceuticals position peaked at $577K in Q2 2020.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Vestmark Advisory Solutions's 13F filing for Q1 2022, filed 27 Apr 2022.